News

Conference Coverage

Examining Predictors of Emergent Thrombocytopenia After Ruxolitinib Treatment Among Patients With Myelofibrosis

01/03/2024

At the 2023 ASH Annual Meeting, Douglas Tremblay, MD, discussed the prevalence and predictors of emergent thrombocytopenia following ruxolitinib treatment among patients with myelofibrosis.

At the 2023 ASH Annual Meeting,...

01/03/2024

Oncology

Conference Coverage

Examining Predictors of Emergent Thrombocytopenia After Ruxolitinib Treatment Among Patients With Myelofibrosis

01/03/2024

Douglas Tremblay , MD;

At the 2023 ASH Annual Meeting, Douglas Tremblay, MD, discussed the prevalence and predictors of emergent thrombocytopenia following ruxolitinib treatment among patients with myelofibrosis.

At the 2023 ASH Annual Meeting,...

01/03/2024

Oncology

Claire Harrison, MD, FRCP, Guy’s and St. Thomas’ NHS Foundation Trust

Conference Coverage

Ruxolitinib Therapy Demonstrates Reduced JAK2 Allele Burden and Improvement in Hematocrit Control and Symptom Burden for Patients With PV

12/21/2023

Claire Harrison , MD;

At the 65th ASH Annual Meeting in San Diego, California, Claire Harrison, MD, FRCP discussed a pooled efficacy analysis that provided further evidence of the benefit of ruxolitinib treatment for patients with polycythemia vera, with or...

At the 65th ASH Annual Meeting...

12/21/2023

Oncology

Pankit Vachhani, MD, O’Neal Comprehensive Cancer Center

Conference Coverage

Platelet Count Response Among Patients With Cytopenic Myelofibrosis Treated With Pacritinib

12/21/2023

Pankit Vachhani , MD;

At the 65th ASH Annual Meeting in San Diego, California, Pankit Vachhani, MD, presented data that platelet count improvement occurred in a subset of patients with myelofibrosis treated with pacritinib.

At the 65th ASH Annual Meeting...

12/21/2023

Oncology

News

Ruxolitinib Exhibits Safety, Efficacy Among Elderly Patients With Therapy-Naïve Myelofibrosis

11/20/2023

Amber Denham ;

Real-world results from a phase 4 study demonstrate that among elderly patients with therapy-naïve myelofibrosis, ruxolitinib treatment yielded safety and efficacy.

Real-world results from a phase...

11/20/2023

Oncology

News

Momelotinib Yields Substantial Symptom Benefits Among Patients With Myelofibrosis

11/08/2023

Amber Denham ;

Patient-reported outcomes from the phase 3 MOMENTUM trial demonstrated that momelotinib provided rapid and durable response benefits among anemic and symptomatic patients with myelofibrosis (MF).

Patient-reported outcomes from...

11/08/2023

Oncology

Ruben A. Mesa, MD, FACP, Atrium Health Wake Forest Baptist Comprehensive Cancer Center

Videos

Novel Advances in the Treatment of Patients With Myelofibrosis

11/07/2023

Ruben A. Mesa , MD, FACP;

At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Ruben A. Mesa, MD, FACP, discusses the latest updates in myelofibrosis treatment.

At the 2023 Lymphoma, Leukemia &...

11/07/2023

Lymphoma, Leukemia & Myeloma Network

Videos

Novel Advances in the Treatment of Patients With Myelofibrosis

11/07/2023

Ruben A. Mesa , MD, FACP;

At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Ruben A. Mesa, MD, FACP, discusses the latest updates in myelofibrosis treatment.

At the 2023 Lymphoma, Leukemia &...

11/07/2023

Lymphoma, Leukemia & Myeloma Network

News

Low-Dose Splenic Radiotherapy Demonstrates Feasibility, Safety in Combination With AlloHSCT Among Patients With Myelofibrosis

10/10/2023

Jordan Kadish ;

Low-dose splenic radiotherapy combined with allogeneic hematopoietic stem cell transplantation demonstrated encouraging safety outcomes and may lead to improvement in splenomegaly and among patients with myelofibrosis, according to a...

Low-dose splenic radiotherapy...

10/10/2023

Oncology

News

Momelotinib Yields Sustained Safety Without Long-Term or Cumulative Toxicity for Patients With Myelofibrosis

10/10/2023

Jordan Kadish ;

A long-term pooled analysis of several phase 3 trials indicated that momelotinib yielded sustained safety among patients with myelofibrosis.

A long-term pooled analysis of...

10/10/2023

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology